Immunotherapy uses the power of your immune system to fight your cancer. One type of immunotherapy is called an immune checkpoint inhibitor. Your immune system has built-in checkpoints that help it ...
Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States. Avelumab (Bavencio, EMD Serono INc), which is a programmed cell ...
ImmunityBio (NasdaqGS:IBRX) completed enrollment early in its pivotal Phase 2 bladder cancer trial for ANKTIVA. Interim ...
A combination of immunotherapy and targeted cancer treatment given before and after surgery may reduce the risk of recurrence and improve survival in ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
Non-Muscle Invasive Bladder Cancer Market · GlobeNewswire Inc. The non-muscle invasive bladder cancer (NMIBC) market size has experienced robust growth, increasing from $3.66 billion in 2025 to an ...
In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for ...
This week in oncology, the FDA expanded the treatment landscape for platinum-resistant ovarian cancer with a new approval, and significant clinical data emerged regarding novel in ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results